TSOI (Therapeutic Solutions International) ROIC %: -198.26% (As of Sep. 2024)


What is Therapeutic Solutions International ROIC %?

Therapeutic Solutions International TSOI -99.00% ROIC % is -198.26% as of Sep. 2024.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Therapeutic Solutions International's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2024 was -198.26%.

As of today (2026-07-04), Therapeutic Solutions International's WACC % is 0.00%. Therapeutic Solutions International's ROIC % is 0.00% (calculated using TTM income statement data). Therapeutic Solutions International earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Therapeutic Solutions International  (OTCPK:TSOI) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Therapeutic Solutions International's WACC % is 0.00%. Therapeutic Solutions International's ROIC % is 0.00% (calculated using TTM income statement data). Therapeutic Solutions International earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Therapeutic Solutions International ROIC % Related Terms

Therapeutic Solutions International ROIC % Historical Data

* Premium members only.

The historical data trend for Therapeutic Solutions International's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therapeutic Solutions International ROIC % Chart

Therapeutic Solutions International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -76.95 -109.53 -118.18 -96.93 -45.50

Therapeutic Solutions International Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.66 -52.25 -65.07 -40.06 -198.26

TSOI vs BPTH, RGBP, HEPA: ROIC % Comparison

For the Biotechnology subindustry, Therapeutic Solutions International's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Therapeutic Solutions International ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Therapeutic Solutions International's ROIC % distribution charts can be found below:

* The bar in red indicates where Therapeutic Solutions International's ROIC % falls into.


Therapeutic Solutions International ROIC % Calculation

Therapeutic Solutions International's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-1.986 * ( 1 - 0% )/( (4.565 + 4.165)/ 2 )
=-1.986/4.365
=-45.50 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.606 - 0.941 - ( 0.018 - max(0, 2.21 - 0.31+0.018))
=4.565

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.292 - 0.941 - ( 0.028 - max(0, 1.9 - 0.086+0.028))
=4.165

Therapeutic Solutions International's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2024 is calculated as:

ROIC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-7.84 * ( 1 - 0% )/( (3.958 + 3.951)/ 2 )
=-7.84/3.9545
=-198.26 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.775 - 0.931 - ( 0.008 - max(0, 1.85 - 0.736+0.008))
=3.958

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.6 - 0.989 - ( 0.009 - max(0, 1.839 - 0.499+0.009))
=3.951

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -198.26% mean?
Therapeutic Solutions International (TSOI) has a ROIC % of -198.26% as of Sep. 2024. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Therapeutic Solutions International and its competitors.
Is Therapeutic Solutions International's ROIC % too high?
Therapeutic Solutions International's current ROIC % is -198.26%.
How does Therapeutic Solutions International's ROIC % compare to BPTH and RGBP?
Therapeutic Solutions International's ROIC % of -198.26% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Therapeutic Solutions International and its competitors. Therapeutic Solutions International's current ROIC % is -198.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Therapeutic Solutions International stock overvalued right now?
Therapeutic Solutions International (TSOI) has a current ROIC % of -198.26%. The current ROIC % is -198.26%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Therapeutic Solutions International (TSOI), the current ROIC % is -198.26% as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Therapeutic Solutions International Business Description

Address 701 Wild Rose Lane, Elk City, ID, USA, 83525
Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for the development of therapeutics in the area of chronic traumatic encephalopathy and traumatic brain injury and Lung Pathology.